Revolution Medicines (RVMD) Investor Update – What You Need to Know

By Harris Dyer • Monday, June 02 15:25 • Permanent Link

With gains of 3.9%, Revolution Medicines was one of the winners on Wall Street today. Its shares are now trading at $40.95 and have logged a 1.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

Revolution Medicines has moved -1.9% over the last year, and the S&P 500 logged a change of 11.9%
RVMD has an average analyst rating of buy and is -43.41% away from its mean target price of $72.36 per share
Its trailing earnings per share (EPS) is $-4.01
Revolution Medicines has a trailing 12 month Price to Earnings (P/E) ratio of -10.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $-4.05 and its forward P/E ratio is -10.1
The company has a Price to Book (P/B) ratio of 3.67 in contrast to the S&P 500's average ratio of 4.74
Revolution Medicines is part of the Health Care sector, which has an average P/E ratio of 22.94 and an average P/B of 3.19
The company has a free cash flow of $-349126624, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.